Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 70.7 kDa. The protein migrates as 95-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human ErbB4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human ErbB4, His Tag (Cat. No. ER4-H5221) at 2 μg/mL (100 μL/well) can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | Tagrisso, 泰瑞沙 | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Endometrial Neoplasms; Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Neoplasm, Residual; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Adenocarcinoma of Lung; Skin Neoplasms; Glioblastoma | Details |
Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Glioma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Uterine Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Hematologic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Liver Diseases; Chordoma; Neuroectodermal Tumors; Neoplasms, Squamous Cell; Glioblastoma; Neoplasms; Renal Insufficiency; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Solid tumours; Head and Neck Neoplasms | Details |
Neratinib Maleate | CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant human neuregulin-1 | rhNRG-1 | Phase 3 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Heart Failure, Diastolic; Heart Failure; Myocardial Infarction; Heart Failure, Systolic | Details |
Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer | Details |
Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Fukang (Shanghai) Health Technology Co Ltd | Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
XZP-5209 | XZP-5209 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
FCN-411 | FCN-411 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.